QualityStocksNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) to Present Clinical and Scientific Findings at Key Oncology Conferences

BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT), a biotechnology company developing targeted, safe treatments for cancer, today announced that it will present clinical and scientific findings at key oncology conferences. According to the update, the company was selected to present a poster at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium, to be held in San Francisco, California from February 28 to March 2, 2019. The poster will highlight findings related to the mechanism of action of BriaCell’s lead candidate, Bria-IMT(TM), as well as BriaDX(TM), the Bria-IMT(TM) companion diagnostic test and Bria-OTS(TM), the company’s off-the-shelf personalized immunotherapy. In addition, BriaCell Founder and Director Dr. Charles L. Wiseman will be featured as a keynote speaker at the 10th Euro Breast Cancer Summit to be held in Paris, France on March 20 – 21, 2019. The company has also been accepted to present a poster at the Annual Meeting for the American Association for Cancer Research (“AACR”) to be held at the Georgia World Congress Center in Atlanta, Georgia from March 29 – April 3, 2019. The poster will summarize molecular and clinical findings that support the advancement of the Bria-OTS(TM) program.

“An estimated 42,000 women will die of breast cancer in 2019 in the U.S. alone, indicating a substantial unmet medical need for a large patient population whose tumors had become resistant to chemotherapy or other therapeutic regimens,” BriaCell President and CEO Dr. Bill Williams stated in the news release. “Currently, there are no effective treatment options for these patients, leaving them with a very poor prognosis and a grim survival outlook. We are excited to share our findings with the scientific and medical community at ASCO-SITC Clinical Immuno-Oncology Symposium and the AACR meeting. We believe that our unique approach is promising and supports personalizing our immunotherapy to match individual patients. HLA typing may serve as a companion diagnostic test, BriaDX(TM), to determine the best match for Bria-IMT(TM) and for Bria-OTS(TM), our off-the-shelf personalized immunotherapy, which is under development for breast cancer patients. Bria-OTS(TM) has the potential to stimulate the immune system in a manner tailored to the patient without the complexities associated with other personalized therapies, to bring hope to advanced breast cancer patients with few effective treatment options. Further studies are merited and in progress, especially for our ongoing combination study of Bria-IMT(TM) with KEYTRUDA®.”

To view the full press release, visit http://ibn.fm/7iBqE

About BriaCell Therapeutics Corp.

BriaCell is an immuno-oncology-focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell is currently conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a combination study with pembrolizumab [Keytruda; manufactured by Merck & Co., Inc.] or ipilimumab [Yervoy; manufactured by Bristol-Myers Squibb Company]. The combination study is listed in ClinicalTrials.gov as NCT03328026. BriaCell is developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing. Bria-OTS, which is expected to cover over 90 percent of the patient population, is designed to produce a potent and selective immune response against the cancer of each patient while eliminating the time, expense and complex manufacturing logistics associated with other personalized immunotherapies. For more information, visit the company’s website at www.BriaCell.com.

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php